Company Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
LP-50, an intravesical formulation for local, intravesical PD-1 inhibition, intended for the treatment of non muscle invasive bladder cancer (NMIBC) Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jonathan Kaufman |
Contact Details
Address: 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 United States | |
| Phone | 412 894 1853 |
| Website | lipella.com |
Stock Details
| Ticker Symbol | LIPO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.75 |
| CIK Code | 0001347242 |
| CUSIP Number | 53630L100 |
| ISIN Number | US53630L1008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer |
| Dr. Michael B. Chancellor M.D. | Co-Founder, Chief Medical Officer and Director |
| Douglas Johnston CPA | Chief Financial Officer |
| Michele Gruber | Director of Operations |
| Janet Okonski | Director of Clinical Operations |
| Katie Johnston | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | 8-K | Current Report |
| Apr 9, 2025 | SCHEDULE 13D/A | Filing |
| Apr 9, 2025 | SCHEDULE 13D/A | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 7, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 424B5 | Filing |
| Apr 4, 2025 | 424B3 | Prospectus |
| Apr 3, 2025 | EFFECT | Notice of Effectiveness |
| Apr 1, 2025 | D | Notice of Exempt Offering of Securities |